small molecule

ZYCLARA

IMIQUIMOD

Loss of exclusivityDecember 2029latest FDA-listed patent expiry
CompanyBAUSCH HEALTH US LLC

Drug detail

Brand nameZYCLARA
Active ingredientIMIQUIMOD
Strength2.5%
Dosage formCREAM
RouteTOPICAL
ModalitySmall molecule
FDA approvalJuly 2011
Marketing statusRX

Listed patents

PatentExpiresType
8222270December 2029use U-68
11318130December 2029use U-68

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

ZYCLARA patent cliff — loss of exclusivity December 2029 | CliffBio